<h2>Revlon Meets Its Match: Public Benefit Corporations Rewrite Delaware's Sale-Duty Doctrine</h2>
Revlon Meets Its Match: Public Benefit Corporations Rewrite Delaware's Sale-Duty Doctrine Delaware corporate law just experienced its most significant doctrinal shift in M&A jurisprudence since Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc. , 506...
Revlon Meets Its Match: Public Benefit Corporations Rewrite Delaware's Sale-Duty Doctrine
Delaware corporate law just experienced its most significant doctrinal shift in M&A jurisprudence since Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., 506 A.2d 173 (Del. 1986). Vice Chancellor Nathan Cook's July 2026 ruling that public benefit corporations (PBCs) are not bound by the classic Revlon duty to maximize short-term sale price doesn't merely tweak existing law—it fundamentally restructures how deal lawyers must approach change-of-control transactions for mission-driven entities. For practitioners, this is not academic: it transforms risk allocation, due diligence protocols, and negotiation leverage in ways that will ripple through private equity and strategic M&A for years.
The Holding: Balancing, Not Maximizing
The Chancery Court held that PBC directors must balance three interests when evaluating sale transactions: (1) stockholder pecuniary interests, (2) the corporation's specified public benefit purposes, and (3) stakeholder interests materially affected by corporate conduct. This "tripartite balancing test" explicitly rejects the Revlon paradigm where traditional Delaware corporations entering a change-of-control must pivot to single-minded price maximization.
What makes this development genuinely consequential is structural. Revlon duties emerged as a judicial response to the uniquely vulnerable position of stockholders when a board has decided to sell the company—the "endgame" scenario where there's no tomorrow for stockholders to recover value. The Chancery's PBC ruling preserves that vulnerability but adds competing fiduciary obligations that may override price maximization. This is not a mere "consideration" of other factors; it's a mandatory balancing act where superior price can lawfully be sacrificed.
Why This Matters for Deal Practice
First, due diligence just got more expensive. Buyers targeting PBCs must now parse charter language with excruciating precision. The "specified public benefit" language in a PBC's certificate of incorporation becomes load-bearing: it defines the scope of legitimate non-price considerations. Deal lawyers will need to model how target boards might weigh mission-alignment against premium offers—and whether that weighing creates actionable disparities in valuation.
Second, "fiduciary out" provisions require redrafting. Traditional merger agreements contain robust fiduciary outs allowing boards to consider superior proposals. For PBCs, these provisions must now accommodate non-price superiority: a lower bid that better advances public benefit purposes may be "superior" under Delaware law even with a lower dollar value. This complicates "no-shop" enforceability and termination fee mechanics.
Third, the "Revlon moment" analysis disappears for PBCs. Under Revlon and its progeny—including QVC Network Inc. v. Liberty Media Corp., 637 A.2d 34 (Del. 1994)—boards of traditional corporations face enhanced scrutiny when they accept controller bids or enter exclusive negotiations. PBC boards face different scrutiny: whether their balancing of interests was reasonable and good-faith, not whether they achieved the highest reasonably available price.
The Strategic Implications
This ruling creates arbitrage opportunities that sophisticated practitioners will exploit. Consider: a traditional C-corp with strong ESG credentials might convert to PBC status pre-sale to preserve board flexibility for mission-aligned transactions. Conversely, activist hedge funds may pressure PBCs to de-convert to unlock Revlon-maximization value. The Delaware Division of Corporions should anticipate a wave of charter amendments.
The decision also complicates private equity exits. Sponsors holding PBC portfolio companies now face boards that may lawfully reject higher bids from financial buyers in favor of lower strategic bids with better stakeholder outcomes. This directly implicates go-shop periods, stapled financing arrangements, and rollover equity structures.
"The court's rejection of Revlon-for-PBCs signals that Delaware's corporate law ecosystem can accommodate pluralistic governance models without collapsing into jurisdictional competition. But it also creates uncertainty: how much price sacrifice is too much?"
Connecting to Broader Trends
This ruling arrives amid Delaware's larger corporate law recalibration. The 2025 SB 21 amendments—upheld by the Delaware Supreme Court in February 2026—similarly restructured fiduciary litigation, but by contracting stockholder rights rather than expanding board discretion. The PBC decision and SB 21 together reveal a jurisprudential theme: Delaware is reinforcing board-centric governance across corporate forms, whether by eliminating Revlon duties for PBCs or by cleansing M&A through independent committees under SB 21, Del. Code Ann. tit. 8, § 144 (as amended).
The Tesla compensation saga—where Chancellor McCormick's muscular fiduciary review was partially reversed—similarly shows Delaware's Supreme Court checking lower-court activism. The PBC ruling, by contrast, originates in Chancery and reflects expansive rather than restrictive judicial interpretation. This divergence suggests the Supreme Court has not adopted a uniform anti-expansion stance; rather, it evaluates whether doctrinal innovation serves Delaware's competitive position as the premier incorporation jurisdiction.
The Bottom Line
For transactional lawyers, this ruling demands immediate attention to PBC-specific playbook revisions. The days of assuming Revlon duties apply universally to Delaware sale transactions are over. Deal teams must now:
- Flag PBC status in every Delaware target screening
- Analyze charter-specified public benefits for M&A materiality
- Structure fairness opinions to address balancing-test compliance
- Revise disclosure schedules for mission-related diligence
The Chancery has given PBC boards a powerful tool: the lawful ability to say "no" to the highest bidder. Whether that tool becomes a shield for legitimate stakeholder governance or a weapon for entrenchment will depend on the next generation of fiduciary litigation—and on how aggressively plaintiffs' bars test the boundaries of "reasonable" balancing.
Tags
Published by AnrakLegal AI